All In Biotech

Drug Trial Radar · NCT05200936

Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

Safety and Efficacy of Repeated Low Dose d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM120) as Treatment for ADHD in Adults: a Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2a Proof of Concept Trial

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

53

Actual

Start

Dec 17, 2021

Primary completion

Nov 6, 2023

Study completion Dec 4, 2023

Sponsor

Lead sponsor
Definium Therapeutics US, Inc.Industry
Sponsor type
Industry
First posted
Jan 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled

Conditions

  • ADHD
  • Attention Deficit Disorder

Interventions

  • MM120Drug

    MM120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM120 manifests primarily visual, as well as auditory, hallucinations.

  • PlaceboOther

    A treatment which is designed to have no therapeutic value.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) SymptomsTime frame: 6 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Maastricht University

    Maastricht, Netherlands

  • University Hospital Basel

    Basel, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.